Matches in SemOpenAlex for { <https://semopenalex.org/work/W2792513383> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W2792513383 abstract "Background: The prognosis of patients with Epidermal Growth Factor Receptor (EGFR) overexpression in inoperable Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN) remains poor. Nimotuzumab is an Anti EGFR humanized monoclonal antibody approved for treatment of LASCCHN, with concurrent chemoradiation. Objective: To assess the efficacy and safety of nimotuzumab with concurrent chemoradiation in inoperable LASCCHN patients. Methodology: This is a single-centre, single arm, retrospective study evaluating 35 patients with histologically confirmed inoperable LASCCHN (stages III-IV). The patients were administered IV cisplatin 50 mg/m2 and IV nimotuzumab 200 mg for 6 - 7 weeks, along with radiotherapy of 6600 - 7000 cGy over 35 fractions. Patients were evaluated over response evaluation criteria in solid tumors (RECIST) criteria 12 weeks after the last cycle of chemotherapy. They were also followed up for overall survival and relapse free survival. Results: The median duration of follow-up was 20 months. The most common site of cancer was oropharynx (68.6%). One patient was lost to follow up. Objective Response Rate (ORR) was observed in 97% of the patients with 17 patients (48.6%) achieving complete response (CR) and 17 patients (48.6%) achieving partial response (PR). The median overall survival was 22.7 months (95% CI: 21.30, 34.27). The median relapse free survival was 16.7 months (95% CI: 9.80, 24.50). Nimotuzumab was safe and well tolerated with few mild, self-limiting adverse events. Conclusion: Nimotuzumab with chemoradiation is a safe and efficacious option in patients with LASCCHN. Larger studies are needed to verify the same." @default.
- W2792513383 created "2018-03-29" @default.
- W2792513383 creator A5008978156 @default.
- W2792513383 creator A5010553636 @default.
- W2792513383 creator A5037879735 @default.
- W2792513383 creator A5043494145 @default.
- W2792513383 creator A5044140891 @default.
- W2792513383 creator A5053565612 @default.
- W2792513383 creator A5058580362 @default.
- W2792513383 creator A5091218970 @default.
- W2792513383 date "2018-01-01" @default.
- W2792513383 modified "2023-09-25" @default.
- W2792513383 title "Nimotuzumab with Concurrent Chemoradiation in Inoperable Locally Advanced Squamous Cell Carcinoma of Head and Neck: An Indian Experience" @default.
- W2792513383 doi "https://doi.org/10.4236/jct.2018.91010" @default.
- W2792513383 hasPublicationYear "2018" @default.
- W2792513383 type Work @default.
- W2792513383 sameAs 2792513383 @default.
- W2792513383 citedByCount "0" @default.
- W2792513383 crossrefType "journal-article" @default.
- W2792513383 hasAuthorship W2792513383A5008978156 @default.
- W2792513383 hasAuthorship W2792513383A5010553636 @default.
- W2792513383 hasAuthorship W2792513383A5037879735 @default.
- W2792513383 hasAuthorship W2792513383A5043494145 @default.
- W2792513383 hasAuthorship W2792513383A5044140891 @default.
- W2792513383 hasAuthorship W2792513383A5053565612 @default.
- W2792513383 hasAuthorship W2792513383A5058580362 @default.
- W2792513383 hasAuthorship W2792513383A5091218970 @default.
- W2792513383 hasBestOaLocation W27925133831 @default.
- W2792513383 hasConcept C121608353 @default.
- W2792513383 hasConcept C126322002 @default.
- W2792513383 hasConcept C141071460 @default.
- W2792513383 hasConcept C143998085 @default.
- W2792513383 hasConcept C197934379 @default.
- W2792513383 hasConcept C2776055544 @default.
- W2792513383 hasConcept C2776530083 @default.
- W2792513383 hasConcept C2776694085 @default.
- W2792513383 hasConcept C2778239845 @default.
- W2792513383 hasConcept C2779438470 @default.
- W2792513383 hasConcept C2779984678 @default.
- W2792513383 hasConcept C31760486 @default.
- W2792513383 hasConcept C509974204 @default.
- W2792513383 hasConcept C71924100 @default.
- W2792513383 hasConceptScore W2792513383C121608353 @default.
- W2792513383 hasConceptScore W2792513383C126322002 @default.
- W2792513383 hasConceptScore W2792513383C141071460 @default.
- W2792513383 hasConceptScore W2792513383C143998085 @default.
- W2792513383 hasConceptScore W2792513383C197934379 @default.
- W2792513383 hasConceptScore W2792513383C2776055544 @default.
- W2792513383 hasConceptScore W2792513383C2776530083 @default.
- W2792513383 hasConceptScore W2792513383C2776694085 @default.
- W2792513383 hasConceptScore W2792513383C2778239845 @default.
- W2792513383 hasConceptScore W2792513383C2779438470 @default.
- W2792513383 hasConceptScore W2792513383C2779984678 @default.
- W2792513383 hasConceptScore W2792513383C31760486 @default.
- W2792513383 hasConceptScore W2792513383C509974204 @default.
- W2792513383 hasConceptScore W2792513383C71924100 @default.
- W2792513383 hasLocation W27925133831 @default.
- W2792513383 hasOpenAccess W2792513383 @default.
- W2792513383 hasPrimaryLocation W27925133831 @default.
- W2792513383 isParatext "false" @default.
- W2792513383 isRetracted "false" @default.
- W2792513383 magId "2792513383" @default.
- W2792513383 workType "article" @default.